Schröder et al Disclosure Two of the authors were paid employees of Solvay Pharmaceuticals GmbH. None of the authors of this article have any other declarable conflict of interest. References 1. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment inter- ventions for Parkinson’s disease: an evidence based assessment. Lancet. 2002;359:1589–1598. 2. Wojtecki L, Südmeyer M, Schnitzler A. The current treatment of Parkinson’s disease. Dtsch Arztebl. 2007;104:A2513–2522. 3. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson’s disease: assessing patient health- related quality of life. Qual Life Res. 2000;9:87–100. 4. Dodel RC, Singer MS, Köhne-Volland R, et al. The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis. pharmacoeconomics. 1998;14:299–312. 5. Dodel RC, Berger K, Oertel WH. Health-related quality-of-life and health- care utilisation in patients with Parkinson’s disease: impact of motor fluc- tuations and dyskinesias. pharmacoeconomics. 2001;19: 1013–1038. 6. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging. 2006;23:693–721. 7. Eggert K, Deuschl G, Gasser T, et al. Leitlinie Parkinson-Syndrome, 2 Ausg. Stuttgart, Thieme, 2005. 8. Klinische “Leitlinien“ der deutschen Gesellschaft für Neurologie. Leitlinie für Diagnostik und Therapie in der Neurologie. Stuttgart, Germany: Thieme; 2003. 9. Oertel WH, Quinn N. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, editors. Neurological Disorders: Course and Treatment. San Diego: Academic Press, 2002;1021–1079. 10. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Mov Disord. 2001;56:S1–S88. 11. Parkinson’s Disease Consensus Working Group (PDCWG). Guidelines for the management of Parkinson’s disease. Hosp Med. 1998;59: 469–480. 12. GKV-Modernisierungsgesetz. Bundesgesetzblatt Jahrgang 2003 Teil I No. 55, ausgegeben zu Bonn am 19. November 2003. Gesetz zur Modernisierung der gesetzlichen Krankenversicherung (GKV- Modernisierungsgesetz – GMG); vom 14. November 2003. 13. Eggert K, Larisch A, Dodel R, Bormann C, Oertel WH. Awareness and knowledge of the clinical practice guideline on Parkinson’s disease among German neurologists. Eur Neurol. 2009;61:216–222. 14. Larisch A, Oertel WH, Eggert K. Attitudes and barriers to clinical prac- tice guidelines in general and to the guideline on Parkinson’s disease. A National Survey of German neurologists in private practice. J Neurol. 2009;256:1681–1688. Dovepress 15. Askmark H, Antonov K, Aquilonius SM. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption – a nation-wide perspective in Sweden. parkinsonism Relat Disord. 2003;9:271–276. 16. Leoni O, Martignoni E, Cosentino M, et al. Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. pharmacoepidemiol Drug Saf. 2002;11: 149–157. 17. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin. 2008;24: 3063–3072. 18. http://www.esomar.org/uploads/pdf/professional-standards/ ICCESOMAR_Code_English.pdf 19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg psychiatry. 1992;55: 181–184. 20. Meara J, Bhowmick BL, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing. 1999;28:99–102. 21. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet. 1977;1:345–349. 22. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population- based study. Neurology. 2005;65:1436–1441. 23. Möller JC, Körner Y, Dodel RC, et al. Pharmacotherapy of Parkinson’s disease in Germany. J Neurol. 2005;252:926–935. 24. Müller T, Voss B, Hellwig K, Josef Stein F, Schulte T, Przuntek H. Treat- ment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic. CNS Drugs. 2004; 18:105–11. 25. Yamamoto M. Practice guidelines for Parkinson’s disease. parkinsonism Rel Disord. 2003;9:S111–S115. 26. Klinische “Leitlinien“ der deutschen Gesellschaft für Neurologie. Leitlinie für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme, 2008. 27. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassess- ment of risks and benefits of dopamine agonists in Parkinson‘s disease. Lancet Neurol. 2009;8:929–937. 28. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–1465. 29. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342: 1317–1322. 30. Grimshaw JM, Eccles M, Thomas R, et al. Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998. J Gen Intern Med. 2006;21 Suppl 2:S14–S20. Neuropsychiatric Disease and Treatment Publish your work in this journal Neuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, and is the official Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal Dovepress journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 110 submit your manuscript | www.dovepress.com Dovepress Neuropsychiatric Disease and Treatment 2011:7